Education
About Us
Working with TipRanks
Follow Us
Tscan Therapeutics, Inc. (TCRX)
:TCRX
TCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.44 - $9.69
Previous CloseN/A
Volume150.47K
Average Volume (3M)465.26K
Market Cap
$94.51M
Enterprise Value$410.36M
Total Cash (Recent Filing)-$41.76M
Total Debt (Recent Filing)$109.07M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
May 13, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding52,314,037
10 Day Avg. Volume529,005
30 Day Avg. Volume465,256
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)33.56
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap4.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.12
Enterprise Value/Ebitda-3.99
Forecast
1Y Price Target
$10.17Price Target Upside508.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe TSC arm outperformed the control arm with a lower relapse rate of 8% compared to 33% in the control arm.
Pipeline ProgressThe company continues to make progress across their pipeline, announcing that the expansion cohorts at dose level 3 of the Phase 1 hematological malignancy study have been opened to further assess safety, as well as translational and efficacy endpoints.
Regulatory SupportThe FDA appears supportive of the proposed primary endpoint for the trial, which is relapse-free survival.
Bears Say
Financial ConcernsTScan ended with $290M in cash, supporting operations into a future period.
Price Target AdjustmentAnalyst maintains a Buy Rating but lowers the Price Target to $9, accounting for dilution.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TCRX FAQ
What was Tscan Therapeutics, Inc.’s price range in the past 12 months?
Tscan Therapeutics, Inc. lowest stock price was $1.44 and its highest was $9.69 in the past 12 months.
What is Tscan Therapeutics, Inc.’s market cap?
Tscan Therapeutics, Inc.’s market cap is $94.51M.
When is Tscan Therapeutics, Inc.’s upcoming earnings report date?
Tscan Therapeutics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Tscan Therapeutics, Inc.’s earnings last quarter?
Tscan Therapeutics, Inc. released its earnings results on Mar 05, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.319 by $0.019.
Is Tscan Therapeutics, Inc. overvalued?
According to Wall Street analysts Tscan Therapeutics, Inc.’s price is currently Undervalued.
Does Tscan Therapeutics, Inc. pay dividends?
Tscan Therapeutics, Inc. does not currently pay dividends.
What is Tscan Therapeutics, Inc.’s EPS estimate?
Tscan Therapeutics, Inc.’s EPS estimate is -0.29.
How many shares outstanding does Tscan Therapeutics, Inc. have?
Tscan Therapeutics, Inc. has 52,314,037 shares outstanding.
What happened to Tscan Therapeutics, Inc.’s price movement after its last earnings report?
Tscan Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.319. Following the earnings report the stock price went down -4.95%.
Which hedge fund is a major shareholder of Tscan Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TCRX
---
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.17 (508.98% Upside)
$10.17 (508.98% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 13.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $385.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.17%
12-Months-Change
Fundamentals
Return on Equity
-65.08%
Trailing 12-Months
Asset Growth
36.37%
Trailing 12-Months
Company Description
Tscan Therapeutics, Inc.
TScan Therapeutics (TCRX) is a biotechnology company focused on developing T-cell receptor (TCR) engineered T-cell therapies for the treatment of cancer. The company operates in the healthcare sector, specifically within the biotechnology and pharmaceuticals industries. TScan's core products involve identifying novel cancer targets and engineering T-cells to recognize and eliminate cancer cells, offering innovative therapeutic options for patients with limited treatment alternatives.
---
TCRX Stock 12 Month Forecast
Average Price Target
$10.17
▲(508.98% Upside)
Technical Analysis
Best Analysts Covering TCRX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-12.58%
reiterated a buy rating 19 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -12.58% per trade.
---